Skip to main content

Topical tacalcitol and 308-nm monochromatic excimer light: a synergistic combination for the treatment of vitiligo

Buy Article:

$51.00 plus tax (Refund Policy)

Abstract:

Background/purpose:

To study and compare the efficacy of combined 308-nm monochromatic excimer light (MEL) therapy with tacalcitol vs. that of MEL 308-nm therapy alone in treatment of vitiligo. Methods:

Thirty-eight patients with vitiligo were enrolled in a single-blind, within patient controlled clinical trial. Symmetrical or nearby lesions were randomly applied with either topical tacalcitol cream or vehicle. Each lesion was treated weekly with the 308-nm MEL, for a total of 12 sessions. Patients were examined at monthly intervals. The mean number of sessions and the cumulative dosage for initial repigmentation were calculated. Result:

Thirty-five patients were evaluated. Treatment with tacalcitol and MEL resulted in higher percentages for excellent repigmentation (25.7%) compared with vehicle and MEL (5.7%) (P<0.05). Percentages for total response were 71.4% and 60%, respectively (P>0.05). The mean±SEM cumulative dose and number of excimer light exposures for initial repigmentation were, respectively, 3.93±0.59 J/cm2 and 4.52±0.49 at the tacalcitol side, and, respectively, 4.99±0.68 J/cm2 and 5.3±0.52 at the vehicle side (P<0.05). Conclusion:

Our results have shown that concurrent topical tacalcitol potentiates the efficacy of the 308-nm MEL in the treatment of vitiligo, and that this combination achieves earlier pigmentation with a lower total dosage.

Keywords: 308-nm MEL; tacalcitol; vitiligo

Document Type: Research Article

DOI: http://dx.doi.org/10.1111/j.1600-0781.2006.00250.x

Affiliations: Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China

Publication date: December 1, 2006

mksg/ppp/2006/00000022/00000006/art00007
dcterms_title,dcterms_description,pub_keyword
6
5
20
40
5

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more